These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 31212653)
1. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer. Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653 [TBL] [Abstract][Full Text] [Related]
2. Detection of PD‑L1 expression and epithelial‑mesenchymal transition of circulating tumor cells in non‑small cell lung cancer. Jiang J; Mo W; Lian X; Cao D; Cheng H; Wang H Exp Ther Med; 2024 Jul; 28(1):294. PubMed ID: 38827467 [TBL] [Abstract][Full Text] [Related]
3. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1. Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545 [TBL] [Abstract][Full Text] [Related]
4. Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients. Togo S; Katagiri N; Namba Y; Tulafu M; Nagahama K; Kadoya K; Takamochi K; Oh S; Suzuki K; Sakurai F; Mizuguchi H; Urata Y; Takahashi K Oncotarget; 2017 May; 8(21):34884-34895. PubMed ID: 28432274 [TBL] [Abstract][Full Text] [Related]
5. Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Asante DB; Morici M; Mohan GRKA; Acheampong E; Spencer I; Lin W; van Miert P; Gibson S; Beasley AB; Ziman M; Calapre L; Meniawy TM; Gray ES Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944844 [TBL] [Abstract][Full Text] [Related]
6. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. Janning M; Kobus F; Babayan A; Wikman H; Velthaus JL; Bergmann S; Schatz S; Falk M; Berger LA; Böttcher LM; Päsler S; Gorges TM; O'Flaherty L; Hille C; Joosse SA; Simon R; Tiemann M; Bokemeyer C; Reck M; Riethdorf S; Pantel K; Loges S Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212989 [TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. Guibert N; Delaunay M; Lusque A; Boubekeur N; Rouquette I; Clermont E; Mourlanette J; Gouin S; Dormoy I; Favre G; Mazieres J; Pradines A Lung Cancer; 2018 Jun; 120():108-112. PubMed ID: 29748004 [TBL] [Abstract][Full Text] [Related]
8. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer. Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320 [TBL] [Abstract][Full Text] [Related]
9. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system Raimondi C; Carpino G; Nicolazzo C; Gradilone A; Gianni W; Gelibter A; Gaudio E; Cortesi E; Gazzaniga P Oncoimmunology; 2017; 6(12):e1315488. PubMed ID: 29209560 [TBL] [Abstract][Full Text] [Related]
10. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients. Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898 [TBL] [Abstract][Full Text] [Related]
11. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135 [TBL] [Abstract][Full Text] [Related]
12. PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). Pantazaka E; Ntzifa A; Roumeliotou A; Lianidou E; Georgoulias V; Kotsakis A; Kallergi G Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009440 [TBL] [Abstract][Full Text] [Related]
13. Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients. Ntzifa A; Strati A; Kallergi G; Kotsakis A; Georgoulias V; Lianidou E Sci Rep; 2021 Jan; 11(1):2313. PubMed ID: 33504904 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer. Kallergi G; Vetsika EK; Aggouraki D; Lagoudaki E; Koutsopoulos A; Koinis F; Katsarlinos P; Trypaki M; Messaritakis I; Stournaras C; Georgoulias V; Kotsakis A Ther Adv Med Oncol; 2018; 10():1758834017750121. PubMed ID: 29383038 [TBL] [Abstract][Full Text] [Related]
15. Detection of Circulating Tumor Cell Molecular Subtype in Pulmonary Vein Predicting Prognosis of Stage I-III Non-small Cell Lung Cancer Patients. Dong J; Zhu D; Tang X; Qiu X; Lu D; Li B; Lin D; Zhou Q Front Oncol; 2019; 9():1139. PubMed ID: 31737568 [No Abstract] [Full Text] [Related]
16. Hexokinase 2 discerns a novel circulating tumor cell population associated with poor prognosis in lung cancer patients. Yang L; Yan X; Chen J; Zhan Q; Hua Y; Xu S; Li Z; Wang Z; Dong Y; Zuo D; Xue M; Tang Y; Herschman HR; Lu S; Shi Q; Wei W Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836566 [TBL] [Abstract][Full Text] [Related]
17. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence. Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991 [TBL] [Abstract][Full Text] [Related]
18. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer. Bian J; Yan K; Liu N; Xu X J Cancer Res Clin Oncol; 2020 Oct; 146(10):2621-2630. PubMed ID: 32661602 [TBL] [Abstract][Full Text] [Related]
19. Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients. Katsarou SD; Messaritakis I; Voumvouraki A; Kakavogiannis S; Κotsakis A; Alkahtani S; Stournaras C; Martin SS; Georgoulias V; Kallergi G J Pers Med; 2022 Jan; 12(2):. PubMed ID: 35207643 [TBL] [Abstract][Full Text] [Related]
20. Circulating tumor cells in pulmonary vein and peripheral arterial provide a metric for PD-L1 diagnosis and prognosis of patients with non-small cell lung cancer. Dong J; Zhu D; Tang X; Lu D; Qiu X; Li B; Lin D; Li L; Liu J; Zhou Q PLoS One; 2019; 14(7):e0220306. PubMed ID: 31348821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]